{"id":"NCT02019277","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer","officialTitle":"An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-05","primaryCompletion":"2016-11-04","completion":"2016-11-04","firstPosted":"2013-12-24","resultsPosted":"2018-07-23","lastUpdate":"2018-09-13"},"enrollment":50,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Nab-paclitaxel","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Pertuzumab","otherNames":["Perjeta"]},{"type":"DRUG","name":"Trastuzumab","otherNames":["Herceptin"]}],"arms":[{"label":"Trastuzumab SC, Pertuzumab, and Taxane","type":"EXPERIMENTAL"}],"summary":"This open-label, multicenter, Phase IIIb study will assess the safety, tolerability and efficacy of a combination therapy of intravenous (IV) pertuzumab (Perjeta), trastuzumab (Herceptin) SC, and taxane chemotherapy (docetaxel, paclitaxel or nab-paclitaxel) as first-line therapy in participants with HER2-positive metastatic breast cancer (mBC). All participants will be treated with 3-week cycles of pertuzumab IV (840 milligrams \\[mg\\] first dose; subsequent doses of 420 mg) and trastuzumab SC (600 milligrams \\[mg\\]). The taxane treatment regimen will be determined by the investigator. Participants will continue therapy until disease progression, unacceptable toxicity, or the participant withdraws consent, whichever occurs first.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs) and Serious AEs","timeFrame":"Baseline up to 28 days after last study drug administration (up to 36 months)","effectByArm":[{"arm":"Trastuzumab, Pertuzumab, and Taxane","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":13,"countries":["Australia"]},"refs":{"pmids":["30922805"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":50},"commonTop":["Diarrhoea","Fatigue","Neuropathy peripheral","Alopecia","Rash"]}}